Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons

Synapse

Volumn 41, Issue 1, 2001, Pages 1-10

  Price, Julie C ^a,b   Lopresti, Brian J ^a   Mason, Neale S ^a   Holt, Daniel P ^a   Huang, Y ^a   Mathis, Chester A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Department of Radiology ^*  (United States)

Author keywords

5 HT2A; 18F altanserin; Imaging; Positron emission tomography (PET); Serotonin receptor

Indexed keywords

4 (4 FLUOROBENZOYL)PIPERIDINE; ALTANSERIN; ALTANSERINOL; DRUG METABOLITE; EPLIVANSERIN; FLUORINE 18; KETANSERIN; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BLOOD BRAIN BARRIER; BOLUS INJECTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; DRUG UPTAKE; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; FLUORINE RADIOISOTOPES; KETANSERIN; MODELS, BIOLOGICAL; PAPIO; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035024365     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.1054     Document Type: Article

References (29)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Control 19:716-723.
2. Bevington PR. 1969. Data reduction and error analysis for the physical sciences. New York: McGraw-Hill. p 204-246.
3. 2 receptors in humans using positron emission tomography. Eur J Nucl Med 21:937-946.
4. Burger C, Buck A. 1996. Tracer kinetic modelling of receptor data with mathematical metabolite correction. Eur J Nucl Med 23:539-545.
5. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Mathis C. 1999. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 21:694-709.
6. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, Cunningham VJ. 2000. A general method to correct PET data for tissue metabolites using a dual scan approach. J Nucl Med 41:706-711.
7. Heykants J, Van Peer A, Woestenborghs R, Gould S, Mills J. 1986. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 31:343-350.
8. Heykants J, Michiels M, Woestenborghs R, Awouters F, Leysen JE, Schuurkes J. 1988. Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat. Arzneim-Forsch/Drug Res 38(I).
9. 18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab 11:898-913.
10. Koeppe RA, Frey KA, Mulholland GK, Kilbourn MR, Buck A, Lee KS, Kuhl DE. 1994. Tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J Cereb Blood Flow Metab 14:85-89.
11. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L. 1991. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med 32:2266-2272.
12. 2 receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton A, Baker C, Juorio A, editors. Drugs as tools in neurotransmitter research. Totowa, NJ: Humana Press. p 299-350.
13. 2 receptor binding sites. Binding properties, brain distribution and functional role. Mol Pharmacol 21:301-304.
14. Lopresti B, Holt D, Mason N, Huang Y, Ruszkiewicz J, Perevuznik J, Price J, Smith G, Mathis C. 1998. Characterization of the radiolabeled metabolites of [F-18]altanserin: implications for kinetic modeling. In: Carson R, Daube-Witherspoon M, Herscovitch P, editors. Quantitative functional brain imaging with PET. San Diego: Academic Press. p 293-298.
15. Marquardt DW. 1963. An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math 2:431-441.
16. Mason NS, Huang Y, Holt D, Perevuznik J, Lopresti B, Mathis C. 1997. Synthesis of two radiolabeled metabolites of [F-18]altanserin. J Label Comp Radiopharm 40:161-162.
17. 2A receptor imaging in man using F-18 altanserin: a new model accounting for labeled metabolites. J Nucl Med 37(5):P109.
18. Pazos A, Probst A, Palacios JM. 1987. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21:123-139.
19. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. 1986. Numerical recipes: the art of scientific computing. Cambridge, UK: Cambridge University Press.
20. 11C WAY 100635 and PET. In: Jones T, et al., editors. Quantification of brain function using PET. San Diego: Academic Press. p 257-261.
21. Price JC, Lopresti B, Mason S, Huang Y, Holt D, Smith GS, Mathis CA. 1998. [F-18]Altanserin PET studies of serotonin-2A binding: examination of nonspecific component. In: Carson R, Daube-Witherspoon M, Herscovitch P, editors. Quantitative functional brain imaging with PET. San Diego: Academic Press. p 427-434.
22. 18F]altanserin bolus injection PET data. II. Consideration of radiolabeled metabolites in humans. Synapse.
23. Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie P, Breliere JC. 1992. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmac Exp Ther 262:759-768.
24. 18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab 15:787-797.
25. 2A receptor binding measured with positron emission tomography and [F-18]altanserin in the human brain. Synapse 30:380-392.
26. 18F]altanserin in human and rodent. Nucl Med Biol 26:601-608.
27. 18F]altanserin. J Nucl Med 41:234-241.
28. Van Peer A, Woestenborghs R, Embrechts L, Heykants J. 1986. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol 31:339-342.
29. Votaw JR, Kessler RM, de Paulis T. 1993. Failure of the three compartment model to describe the pharmacokinetics in brain of a high affinity substituted benzamide. Synapse 15:177-190.